Prospective, Multicentre, Observational Study On Fatigue- And Hand-foot Syndrome-related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor As First-line Treatment (Troya Study).

Trial Profile

Prospective, Multicentre, Observational Study On Fatigue- And Hand-foot Syndrome-related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor As First-line Treatment (Troya Study).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Pazopanib (Primary) ; Sorafenib (Primary) ; Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms TROYA
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 14 Jan 2017 Status changed from recruiting to not yet recruiting.
    • 22 Dec 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top